What is the current valuation of the India heparin market in 2024?

The overall market valuation was $593.4 Million in 2024. Read More

What is the projected market size for the India heparin market by 2035?

The projected valuation for 2035 is $882.3 Million. Read More

What is the expected CAGR for the India heparin market during the forecast period 2025 - 2035?

The expected CAGR for the India heparin market during the forecast period 2025 - 2035 is 3.67%. Read More

Which companies are the key players in the India heparin market?

Key players in the market include Baxter International Inc, Sanofi, Pfizer Inc, Novartis AG, Boehringer Ingelheim GmbH, Mylan N.V., Teva Pharmaceutical Industries Ltd, and Aspen Pharmacare Holdings Limited. Read More

What are the main product segments in the India heparin market?

The main product segments are Unfractionated Heparin (UFH) and Low Molecular Weight Heparin (LMWH), with valuations of $200.0 - $300.0 Million and $393.4 - $582.3 Million, respectively. Read More

What sources of heparin are utilized in the India market?

The sources of heparin in the market are Bovine and Porcine, with valuations of $200.0 - $300.0 Million and $393.4 - $582.3 Million, respectively. Read More

What are the primary applications of heparin in India?

Primary applications include Deep Vein Thrombosis & Pulmonary Embolism, Atrial Fibrillation, Heart Attacks, Stroke, and others, with valuations ranging from $43.4 Million to $290.0 Million. Read More

What routes of administration are commonly used for heparin in India?

Common routes of administration are Intravenous Infusion and Subcutaneous Injection, with valuations of $200.0 - $300.0 Million and $393.4 - $582.3 Million, respectively. Read More

Who are the main end users of heparin in India?

Main end users include Hospitals & ASCS, Clinics, and others, with valuations of $356.0 - $525.0 Million, $150.0 - $220.0 Million, and $87.4 - $137.3 Million, respectively. Read More

How does the India heparin market compare to other regions?

While specific regional comparisons are not provided, the growth trajectory and key players suggest a competitive landscape in the India heparin market. Read More

India Heparin Market

ID: MRFR/MED/50587-HCR

200 Pages

Satyendra Maurya

Last Updated: February 06, 2026

India Heparin Market Research Report: Size, Share, Trend Analysis By Product (Unfractionated Heparin (UFH), Low Molecular Weight Heparin (LMWH), By Source (Bovine, Porcine), By Applications (Deep Vein Thrombosis & Pulmonary Embolism, Atrial Fibrillation, Heart Attacks, Stroke, Others), By Route of Administration (Intravenous Infusion, Subcutaneous Injection) and By End Users (Hospitals & ASCS, Clinics, Others) - Growth Outlook & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Download PDF

Certified Researchers

Customize Report

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Chemicals and Materials, BY Product (USD Million)
  1. 4.1.1 Unfractionated Heparin (UFH)
  2. 4.1.2 Low Molecular Weight Heparin (LMWH)
2. 4.2 Chemicals and Materials, BY Source (USD Million)
  1. 4.2.1 Bovine
  2. 4.2.2 Porcine
3. 4.3 Chemicals and Materials, BY Application (USD Million)
  1. 4.3.1 Deep Vein Thrombosis & Pulmonary Embolism
  2. 4.3.2 Atrial Fibrillation
  3. 4.3.3 Heart Attacks
  4. 4.3.4 Stroke
  5. 4.3.5 Others
4. 4.4 Chemicals and Materials, BY Route of Administration (USD Million)
  1. 4.4.1 Intravenous Infusion
  2. 4.4.2 Subcutaneous Injection
5. 4.5 Chemicals and Materials, BY End user (USD Million)
  1. 4.5.1 Hospitals & ASCS
  2. 4.5.2 Clinics
  3. 4.5.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Chemicals and Materials
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Chemicals and Materials
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Baxter International Inc (US)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Sanofi (FR)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Pfizer Inc (US)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis AG (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Boehringer Ingelheim GmbH (DE)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Mylan N.V. (US)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Teva Pharmaceutical Industries Ltd (IL)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Aspen Pharmacare Holdings Limited (ZA)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 INDIA MARKET ANALYSIS BY PRODUCT
3. 6.3 INDIA MARKET ANALYSIS BY SOURCE
4. 6.4 INDIA MARKET ANALYSIS BY APPLICATION
5. 6.5 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
6. 6.6 INDIA MARKET ANALYSIS BY END USER
7. 6.7 KEY BUYING CRITERIA OF CHEMICALS AND MATERIALS
8. 6.8 RESEARCH PROCESS OF MRFR
9. 6.9 DRO ANALYSIS OF CHEMICALS AND MATERIALS
10. 6.10 DRIVERS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
11. 6.11 RESTRAINTS IMPACT ANALYSIS: CHEMICALS AND MATERIALS
12. 6.12 SUPPLY / VALUE CHAIN: CHEMICALS AND MATERIALS
13. 6.13 CHEMICALS AND MATERIALS, BY PRODUCT, 2024 (% SHARE)
14. 6.14 CHEMICALS AND MATERIALS, BY PRODUCT, 2024 TO 2035 (USD Million)
15. 6.15 CHEMICALS AND MATERIALS, BY SOURCE, 2024 (% SHARE)
16. 6.16 CHEMICALS AND MATERIALS, BY SOURCE, 2024 TO 2035 (USD Million)
17. 6.17 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 (% SHARE)
18. 6.18 CHEMICALS AND MATERIALS, BY APPLICATION, 2024 TO 2035 (USD Million)
19. 6.19 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
20. 6.20 CHEMICALS AND MATERIALS, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Million)
21. 6.21 CHEMICALS AND MATERIALS, BY END USER, 2024 (% SHARE)
22. 6.22 CHEMICALS AND MATERIALS, BY END USER, 2024 TO 2035 (USD Million)
23. 6.23 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 India MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY PRODUCT, 2025-2035 (USD Million)
  2. 7.2.2 BY SOURCE, 2025-2035 (USD Million)
  3. 7.2.3 BY APPLICATION, 2025-2035 (USD Million)
  4. 7.2.4 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Million)
  5. 7.2.5 BY END USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Customize Report

India Chemicals and Materials Market Segmentation

Chemicals and Materials By Product (USD Million, 2025-2035)

Unfractionated Heparin (UFH)
Low Molecular Weight Heparin (LMWH)

Chemicals and Materials By Source (USD Million, 2025-2035)

Bovine
Porcine

Chemicals and Materials By Application (USD Million, 2025-2035)

Deep Vein Thrombosis & Pulmonary Embolism
Atrial Fibrillation
Heart Attacks
Stroke
Others

Chemicals and Materials By Route of Administration (USD Million, 2025-2035)

Intravenous Infusion
Subcutaneous Injection

Chemicals and Materials By End user (USD Million, 2025-2035)

Hospitals & ASCS
Clinics
Others

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”